恶性小肠梗阻患者的经空肠造口支架置入术
本研究回顾性纳入23例因晚期腹盆腔恶性肿瘤导致恶性小肠梗阻的患者,于2009年3月至2016年12月行经空肠造口支架置入术。技术成功率为95.7%(22/23),肠减压经小肠造影(n=21)和CT(n=16)证实,梗阻症状部分或完全改善,摄食能力评分提高(p<0.0001)。主要并发症发生率为13.0%(3/23),包括局限性腹膜炎2例和肠穿孔1例,均经保守治疗成功。结论认为该技术有效、技术上可行,症状改善明显,并发症虽非罕见但可保守处理。
要点
- 技术成功率95.7%(22/23),肠减压经小肠造影和CT证实。
- 梗阻症状部分改善9例、完全改善13例,摄食能力评分提高(p<0.0001)。
- 主要并发症13.0%(3/23),局限性腹膜炎2例、肠穿孔1例,均保守治疗成功。
核心结论
- 经空肠造口支架置入术是恶性小肠梗阻的有效治疗方法,技术可行率高(95.7%),症状改善明显,并发症虽非罕见但可保守处理。
研究设计与样本
- 回顾性分析,纳入23例(年龄20-81岁)因晚期腹盆腔恶性肿瘤导致一处(n=20)或两处(n=3)恶性小肠梗阻的患者,于2009年3月至2016年12月行经空肠造口支架置入术;在梗阻上游30-100 cm处经皮创建空肠造口,随即经造口置入支架。
诊断标准与关键数值
- 技术成功定义为支架成功置入,22/23例(95.7%)成功。
- 肠减压经小肠造影(n=21)和CT(n=16)证实。
- 梗阻症状采用3点量表评估,术后2周内部分改善9例、完全改善13例。
- 摄食能力采用4点量表评估,提高3分1例、2分7例、1分14例(p<0.0001)。
- 主要并发症3例(13.0%),包括局限性腹膜炎2例和肠穿孔1例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The objective of our study was to evaluate the clinical effectiveness and safety of transjejunostomy stent placement in patients with malignant small-bowel obstructions (SBOs).
MATERIALS AND METHODS: Twenty-three patients (age range, 20-81 years) who underwent transjejunostomy stent placement between March 2009 and December 2016 for one (n = 20) or two (n = 3) malignant SBOs from advanced abdominal and pelvic malignancies were included in our study. Percutaneous jejunostomy was created 30-100 cm upstream to malignant SBOs and was immediately followed by stent placement through the jejunostomy stoma during the same session. A retrospective analysis was conducted for technical success, bowel decompression, improvement of obstructive symptoms (3-point scale), improvement of food intake capacity (4-point scale), and procedure-related complications.
RESULTS: Stent placement was technically successful in 22 of 23 patients (95.7%). Bowel decompression was confirmed by enterography (n = 21) and CT (n = 16). Obstructive symptoms improved partially (n = 9) or completely (n = 13) within 2 weeks after the procedure. Food intake capacity improved by 3 points in one patient, 2 points in seven patients, and 1 point in 14 patients (p < 0.0001). Major complications (n = 3, 13.0%), including localized peritonitis (n = 2) and bowel perforation (n = 1), were successfully treated conservatively.
CONCLUSION: Transjejunostomy stent placement is an effective treatment in patients with malignant SBOs. It is technically feasible in most patients (95.7%) and provides substantial symptomatic improvement. Procedure-related complications are not rare but can be managed conservatively.
引用
- Kim J, Yoon CJ, Seong NJ, et al. Transjejunostomy Stent Placement in Patients With Malignant Small-Bowel Obstructions. AJR Am J Roentgenol. 2018. PMID: 30160991. doi:10.2214/AJR.18.19599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。